PE20120080A1 - Anticuerpos anti-notch2 y metodos de uso - Google Patents

Anticuerpos anti-notch2 y metodos de uso

Info

Publication number
PE20120080A1
PE20120080A1 PE2011000807A PE2011000807A PE20120080A1 PE 20120080 A1 PE20120080 A1 PE 20120080A1 PE 2011000807 A PE2011000807 A PE 2011000807A PE 2011000807 A PE2011000807 A PE 2011000807A PE 20120080 A1 PE20120080 A1 PE 20120080A1
Authority
PE
Peru
Prior art keywords
seq
nos
methods
selected sequences
notch2
Prior art date
Application number
PE2011000807A
Other languages
English (en)
Spanish (es)
Inventor
Christian W Siebel
Yan Wu
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41349057&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20120080(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of PE20120080A1 publication Critical patent/PE20120080A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PE2011000807A 2008-10-01 2009-09-30 Anticuerpos anti-notch2 y metodos de uso PE20120080A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10191708P 2008-10-01 2008-10-01

Publications (1)

Publication Number Publication Date
PE20120080A1 true PE20120080A1 (es) 2012-02-17

Family

ID=41349057

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011000807A PE20120080A1 (es) 2008-10-01 2009-09-30 Anticuerpos anti-notch2 y metodos de uso

Country Status (18)

Country Link
US (5) US8404239B2 (enExample)
EP (1) EP2334331B1 (enExample)
JP (2) JP5710487B2 (enExample)
KR (1) KR101712214B1 (enExample)
CN (1) CN102170909B (enExample)
AR (1) AR073717A1 (enExample)
AU (1) AU2009298569A1 (enExample)
BR (1) BRPI0913827A2 (enExample)
CA (1) CA2736429A1 (enExample)
CL (1) CL2011000711A1 (enExample)
ES (1) ES2541726T3 (enExample)
IL (1) IL211623A0 (enExample)
MX (1) MX2011002928A (enExample)
PE (1) PE20120080A1 (enExample)
RU (1) RU2580029C2 (enExample)
TW (1) TW201018484A (enExample)
WO (1) WO2010039832A1 (enExample)
ZA (1) ZA201101651B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2413087T3 (es) 2006-06-13 2013-07-15 Oncomed Pharmaceuticals, Inc. Composiciones y métodos para el diagnóstico y tratamiento del cáncer
JP5618544B2 (ja) 2007-01-24 2014-11-05 オンコメッドファーマシューティカルズ インコーポレイテッド 癌の診断および処置のための組成物および方法
US9132189B2 (en) 2008-07-08 2015-09-15 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
ME02069B (me) 2008-07-08 2015-05-20 Oncomed Pharm Inc Vezujuci agensi notch1 receptora i postupci njihove primene
CN102170909B (zh) * 2008-10-01 2015-11-25 霍夫曼-拉罗奇有限公司 抗-notch2抗体和使用方法
US8906649B2 (en) 2010-09-27 2014-12-09 Janssen Biotech, Inc. Antibodies binding human collagen II
ES2757857T3 (es) * 2010-09-27 2020-04-30 Janssen Biotech Inc Anticuerpos de unión a colágeno II humano
MX2014004074A (es) * 2011-10-05 2014-06-05 Genentech Inc Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2.
US20130323266A1 (en) * 2012-05-16 2013-12-05 Oncomed Pharmaceuticals, Inc. Methods for treating cancer with notch2/3 antibodies
RU2666990C2 (ru) 2012-08-13 2018-09-13 Дженентек, Инк. Антитела к jagged и способы их применения
EP2970468B1 (en) 2013-03-13 2021-07-07 Novartis AG Notch2 binding molecules for treating respiratory diseases
AU2014236815B2 (en) 2013-03-15 2019-04-04 Genentech, Inc. Compositions and methods for diagnosis and treatment of hepatic cancers
JP6571115B2 (ja) 2014-02-12 2019-09-04 ジェネンテック， インコーポレイテッド 抗ｊａｇｇｅｄ１抗体及び使用方法
WO2016007775A1 (en) 2014-07-11 2016-01-14 Genentech, Inc. Notch pathway inhibition
US10716829B2 (en) * 2015-09-26 2020-07-21 National Health Research Institutes Method and composition for treatment of hair loss
GB201521447D0 (en) 2015-12-04 2016-01-20 Ucb Biopharma Sprl De novo antibody design
US10858443B2 (en) 2017-05-31 2020-12-08 Trustees Of Boston University Synthetic notch protein for modulating gene expression
PH12023550112A1 (en) * 2020-07-17 2024-06-24 Genentech Inc Anti-notch2 antibodies and methods of use
WO2024216505A1 (zh) * 2023-04-18 2024-10-24 上海洛启生物医药技术有限公司 抗Notch2纳米抗体及其应用
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3896111A (en) 1973-02-20 1975-07-22 Research Corp Ansa macrolides
US4151042A (en) 1977-03-31 1979-04-24 Takeda Chemical Industries, Ltd. Method for producing maytansinol and its derivatives
US4137230A (en) 1977-11-14 1979-01-30 Takeda Chemical Industries, Ltd. Method for the production of maytansinoids
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4265814A (en) 1978-03-24 1981-05-05 Takeda Chemical Industries Matansinol 3-n-hexadecanoate
JPS5562090A (en) 1978-10-27 1980-05-10 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164687A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS5566585A (en) 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS55164685A (en) 1979-06-08 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164686A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4309428A (en) 1979-07-30 1982-01-05 Takeda Chemical Industries, Ltd. Maytansinoids
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US5053394A (en) 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
IE20030749A1 (en) 1991-05-03 2003-11-12 Indiana University Foundation Human notch and delta binding domains in torporythmic proteins, and methods based thereon
US5786158A (en) 1992-04-30 1998-07-28 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
US20050112121A1 (en) 1992-04-30 2005-05-26 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
RU2139731C1 (ru) 1992-11-13 1999-10-20 Айдек Фармасьютикалс Корпорейшн (US Способ лечения, антитела, гибридома
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5780300A (en) 1995-09-29 1998-07-14 Yale University Manipulation of non-terminally differentiated cells using the notch pathway
US20050158859A1 (en) 1995-09-29 2005-07-21 Yale University Manipulation of non-terminally differentiated cells using the Notch pathway
US6692919B1 (en) 1997-07-23 2004-02-17 Yale University Activated forms of notch and methods based thereon
US6436650B1 (en) 1997-07-23 2002-08-20 Yale University Activated forms of notch and methods based thereon
AU768269B2 (en) 1998-10-02 2003-12-04 Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The Apoptosis inducing agents and methods
US8084258B2 (en) 1999-07-12 2011-12-27 University Of Basel Manipulation of tissue of organ type using the notch pathway
AU2001292750B2 (en) 2000-09-22 2005-07-14 Genentech, Inc. Notch receptor agonists and uses
EP2295575A3 (en) 2000-12-04 2011-07-06 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US7755007B2 (en) 2003-04-17 2010-07-13 K&H Manufacturing, Inc Heated pet mat
CA2554779A1 (en) 2004-02-03 2005-08-18 The Regents Of The University Of Michigan Compositions and methods for characterizing, regulating, diagnosing, and treating cancer
US20070077245A1 (en) 2004-08-04 2007-04-05 The Brigham And Women's Hospital, Inc. NOTCH mutations leading to increased receptor signaling
WO2006053063A2 (en) 2004-11-05 2006-05-18 The Regents Of The University Of California Notch-1 assay to detect neurodegenerative diseases
WO2006068822A1 (en) 2004-12-20 2006-06-29 Genentech, Inc. Notch receptor agonists and uses
JP5489465B2 (ja) 2005-12-16 2014-05-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｄｌｌ４アンタゴニストによって腫瘍増殖を阻害する治療方法
US20080241150A1 (en) * 2006-05-15 2008-10-02 The Brigham And Women's Hospital, Inc. Functional negative regulatory domain sequences from human NOTCH1 and 2 and isolated LNR domains from human NOTCH1
ES2413087T3 (es) * 2006-06-13 2013-07-15 Oncomed Pharmaceuticals, Inc. Composiciones y métodos para el diagnóstico y tratamiento del cáncer
RU2461569C2 (ru) 2006-10-19 2012-09-20 Дженентек, Инк. Агонистические антитела против notch3 и их применение для лечения notch3-ассоциированных заболеваний
KR101568049B1 (ko) 2006-12-18 2015-11-11 제넨테크, 인크. 항-ｎｏｔｃｈ3 길항제 항체 및 ｎｏｔｃｈ3-관련 질환의 예방 및 치료에 있어서 그의 용도
JP5618544B2 (ja) * 2007-01-24 2014-11-05 オンコメッドファーマシューティカルズ インコーポレイテッド 癌の診断および処置のための組成物および方法
PE20090321A1 (es) 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
ME02069B (me) 2008-07-08 2015-05-20 Oncomed Pharm Inc Vezujuci agensi notch1 receptora i postupci njihove primene
CN102170909B (zh) * 2008-10-01 2015-11-25 霍夫曼-拉罗奇有限公司 抗-notch2抗体和使用方法
EP3431501A1 (en) * 2009-06-18 2019-01-23 Pfizer Inc Anti notch-1 antibodies

Also Published As

Publication number Publication date
KR20110061600A (ko) 2011-06-09
US20150104461A1 (en) 2015-04-16
JP2015145379A (ja) 2015-08-13
RU2011117237A (ru) 2012-11-10
BRPI0913827A2 (pt) 2020-12-29
US20180057589A1 (en) 2018-03-01
US20140037643A1 (en) 2014-02-06
WO2010039832A1 (en) 2010-04-08
US20170204175A9 (en) 2017-07-20
IL211623A0 (en) 2011-05-31
AU2009298569A1 (en) 2010-04-08
CN102170909A (zh) 2011-08-31
TW201018484A (en) 2010-05-16
US20140314782A1 (en) 2014-10-23
CL2011000711A1 (es) 2012-07-20
MX2011002928A (es) 2011-04-11
US8404239B2 (en) 2013-03-26
AR073717A1 (es) 2010-11-24
JP2012504634A (ja) 2012-02-23
EP2334331A1 (en) 2011-06-22
CA2736429A1 (en) 2010-04-08
EP2334331B1 (en) 2015-04-29
RU2580029C2 (ru) 2016-04-10
ZA201101651B (en) 2012-06-27
CN102170909B (zh) 2015-11-25
KR101712214B1 (ko) 2017-03-03
US20100080808A1 (en) 2010-04-01
JP5710487B2 (ja) 2015-04-30
ES2541726T3 (es) 2015-07-23

Similar Documents

Publication Publication Date Title
PE20120080A1 (es) Anticuerpos anti-notch2 y metodos de uso
PE20141722A1 (es) Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t
PE20120553A1 (es) Anticuerpos anti-fgfr3
ES2685424T3 (es) Anticuerpos anti-Jagged1 y procedimientos de uso
ES2628108T3 (es) Anticuerpos multiespecíficos
PE20121023A1 (es) Anticuerpos e inmunoconjugados
NZ712765A (en) Antibodies that bind csf1r
ES2571129T3 (es) Anticuerpos anti-CTLA4 humanizados
BR112018006579A2 (pt) anticorpos anti-humanos cd19 humanizados e métodos de uso
PE20120878A1 (es) ANTICUERPOS ANTI-FcRH5 E INMUNOCONJUGADOS
ES2776179T3 (es) Anticuerpos dirigidos contra determinantes de la superficie de S. aureus
AR076030A1 (es) Anticuerpos anti-fcrh5 (fc-receptor homologo) e inmunoconjugados y metodos de uso
PE20141693A1 (es) Metodos para tratar el cancer por el uso de antagonistas de union al eje pd-1e inhibidores de mek
PE20150211A1 (es) Anticuerpos e inmunoconjugados anti-cd79b
PE20150025A1 (es) Anticuerpos e inmunoconjugados contra ly6e y metodos de uso
AR091702A1 (es) Anticuerpos anti-cd79b e inmunoconjugados
NZ610294A (en) Human antibodies to human tnf-like ligand 1a (tl1a)
CO6220835A2 (es) Anticuerpos anti-robo4 y sus usos
NZ590890A (en) Neutralizing anti-influenza a virus antibodies and uses thereof
NZ608660A (en) Anti-cd48 antibodies and uses thereof
NZ605980A (en) Anti-fap antibodies and methods of use
PE20170687A1 (es) Proteinas de enlace a cd127
AR096364A1 (es) Anticuerpos receptores de antitransferina y métodos de uso
PE20161571A1 (es) Anticuerpos anti-ox40 y metodos de uso
RU2013158986A (ru) АНТИ-CD79b АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ

Legal Events

Date Code Title Description
FC Refusal